by acaballero | Mar 13, 2024 | Industry insights
Written by Mark Pennington, Consultant Health Economist With the UK’s National Health Service (NHS) facing an unprecedented patient demand for healthcare, there is increasing interest in artificial intelligence (AI) and how it can support healthcare diagnoses....
by acaballero | Feb 1, 2023 | Industry insights
Written by Oliver Burn, Consultant Health Economist, and Margaret Petrou, Consultant Health Economist Adapting a global economic model for Health Technology Assessment (HTA) submissions in several countries can be challenging, as requirements can vary considerably...
by acaballero | Nov 8, 2022 | Industry insights
Written by Mark Pennington, Consultant Health Economist A National Institute for Health and Care Excellence (NICE) recommendation can open the door to widespread adoption for a new medical device. But does getting a NICE recommendation require extensive evidence on...
by Rachel Montague | Jul 25, 2022 | Industry insights
Written by Beth Hancock, Senior Consultant Health Economist Pharmaceutical companies often develop global cost-effectiveness and budget impact models, with the aim of adapting them for specific countries. In principle, this is an efficient and streamlined process, but...
by Rachel Montague | Jun 17, 2022 | Industry insights
Written by Alec Miners, Head of Health Economics The National Institute for Health and Care Excellence’s (NICE’s) new processes and methods guide includes several important changes to the way submitted economic evaluations should be conducted (1). While the headline...
by Rachel Montague | Jun 7, 2022 | Industry insights
Written by Pip White, Principal Medical Writer The IMF The Innovative Medicines Fund (IMF) launched this month (June 2022) to support faster access to non-cancer drugs. This process involves National Health Service (NHS) England and the National Institute for Health...
